stockrow
Saturday 7 November 2026
Export BSEM’s income statement to Excel — free account
BioStem Technologies, Inc.
BSEM Healthcare Biotechnology
- Revenue
- −28.0%
- EPS
- −86,766.7%
Quarter to June 2026, against a year earlier
1.13
0.09
+8.65%
Follow BSEM
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 3.72 |
+8 more quarters Free account |
P/S ratio |
1.65 | 1.80 | 0.61 | 0.40 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | |
P/B ratio |
2.07 | 1.74 | 1.63 | 0.00 | |
Price to Tangible BV |
12.11 | 1.75 | 1.65 | 0.00 | |
EV/Sales |
1.45 | 1.02 | 0.33 | 0.40 | |
EV/EBITDA |
2.75 | 1.43 | 0.37 | 0.42 | |
EV/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/FCF |
0.00 | 0.00 | 0.00 | 0.00 | |
Quick Ratio |
0.64 | — | 3.66 | — | |
Current Ratio |
0.98 | — | 4.12 | — | |
Net Debt/EBITDA |
0.83 | 0.00 | (2.93) | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | — | 0.00 | — | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
9.29% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
149.62% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.47 | 0.00 | 0.01 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.01) | 0.49 | 0.53 | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(46.81%) | (25.41%) | (9.17%) | 26.88% | |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | |
Revenue per Share |
0.46 | 0.36 | 0.60 | 0.63 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.40 | 0.00 | 1.76 | 0.00 | |
Shareholders Equity per Share |
1.59 | 0.00 | 2.34 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.59 | 0.00 | 2.34 | 0.00 | |
EV/EBIT |
2.75 | 1.43 | 0.37 | 0.42 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
3.13 | 2.53 | 0.68 | 0.42 | |
| Other line items | |||||
Working Capital |
(0.42) | — | 33.62 | — | |
Net Current Asset Value |
(0.42) | — | 33.51 | — | |
Average Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026